94 related articles for article (PubMed ID: 24506837)
41. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
[TBL] [Abstract][Full Text] [Related]
42. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits.
Choi JS; Han HK
J Pharm Pharmacol; 2004 Dec; 56(12):1537-42. PubMed ID: 15563760
[TBL] [Abstract][Full Text] [Related]
43. Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats.
Varanasi KK; Potharaju S; Rajak S; Veeraraghavan S; Mallick P; Vakkalanka SK
Methods Find Exp Clin Pharmacol; 2008 Sep; 30(7):537-42. PubMed ID: 18985182
[TBL] [Abstract][Full Text] [Related]
44. Development of a simple LC-MS/MS method for the determination of febuxostat in human plasma and its application to a bioequivalence study.
Shi Z; Liu J; Hu XJ; ShenTu JZ
Pharmazie; 2013 Jun; 68(6):396-400. PubMed ID: 23875244
[TBL] [Abstract][Full Text] [Related]
45. Enhanced oral bioavailability of breviscapine after encapsulation in a liposomal formulation.
Zhong HJ; Deng YJ; Yang BH; Li CL; Du S
Pharmazie; 2005 Jun; 60(6):475-6. PubMed ID: 15997842
[TBL] [Abstract][Full Text] [Related]
46. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
Chung JH; Choi DH; Choi JS
Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
[TBL] [Abstract][Full Text] [Related]
47. Influence of Polysorbate 60 on Formulation Properties and Bioavailability of Morin-Loaded Nanoemulsions with and without Low-Saponification-Degree Polyvinyl Alcohol.
Ikeuchi-Takahashi Y; Kobayashi A; Ishihara C; Matsubara T; Matsubara H; Onishi H
Biol Pharm Bull; 2018; 41(5):754-760. PubMed ID: 29709912
[TBL] [Abstract][Full Text] [Related]
48. Abelmoschi Corolla non-flavonoid components altered the pharmacokinetic profile of its flavonoids in rat.
Lu L; Qian D; Guo J; Qian Y; Xu B; Sha M; Duan J
J Ethnopharmacol; 2013 Jul; 148(3):804-11. PubMed ID: 23702043
[TBL] [Abstract][Full Text] [Related]
49. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine.
Dorababu M; Nishimura A; Prabha T; Naruhashi K; Sugioka N; Takada K; Shibata N
Biomed Pharmacother; 2009 Nov; 63(9):697-702. PubMed ID: 19819100
[TBL] [Abstract][Full Text] [Related]
50. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic interaction between fluvastatin and diltiazem in rats.
Choi JS; Piao YJ; Han HK
Biopharm Drug Dispos; 2006 Dec; 27(9):437-41. PubMed ID: 17009339
[TBL] [Abstract][Full Text] [Related]
52. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
53. Reduced prehepatic extraction of nicardipine in the presence of pioglitazone in rats.
Choi JS; Koh YY; Chung JH; Choi DH; Han HK
J Pharm Pharmacol; 2008 Oct; 60(10):1403-7. PubMed ID: 18812034
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of pidotimod in rats and dogs.
Coppi G; Silingardi S
Arzneimittelforschung; 1994 Dec; 44(12A):1460-4. PubMed ID: 7857342
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats.
Moon YJ; Morris ME
Mol Pharm; 2007; 4(6):865-72. PubMed ID: 17970592
[TBL] [Abstract][Full Text] [Related]
56. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
57. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S
Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
[TBL] [Abstract][Full Text] [Related]
58. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive cytotoxic evaluation of morin, a bioflavonoid against verapamil on rat gastrointestinal epithelium for novel pharmaceutical application involving P-glycoprotein inhibition.
Surampalli G; Nanjwade BK; Patil PA
J Pharm Pharmacol; 2015 Aug; 67(8):1083-99. PubMed ID: 25864533
[TBL] [Abstract][Full Text] [Related]
60. Development and characterization of morin hydrate-loaded micellar nanocarriers for the effective management of Alzheimer's disease.
Singh M; Thakur V; Deshmukh R; Sharma A; Rathore MS; Kumar A; Mishra N
J Microencapsul; 2018 Mar; 35(2):137-148. PubMed ID: 29448848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
